Sarepta Therapeutics Inc (SRPT) Position Trimmed by Guggenheim Capital LLC

Guggenheim Capital LLC lowered its stake in Sarepta Therapeutics Inc (NASDAQ:SRPT) by 21.9% during the 4th quarter, HoldingsChannel reports. The fund owned 65,347 shares of the biotechnology company’s stock after selling 18,370 shares during the quarter. Guggenheim Capital LLC’s holdings in Sarepta Therapeutics were worth $3,635,000 at the end of the most recent quarter.

A number of other large investors also recently added to or reduced their stakes in SRPT. Nationwide Fund Advisors boosted its holdings in Sarepta Therapeutics by 11.7% in the third quarter. Nationwide Fund Advisors now owns 32,906 shares of the biotechnology company’s stock valued at $1,493,000 after acquiring an additional 3,440 shares in the last quarter. Prudential Financial Inc. bought a new stake in Sarepta Therapeutics in the third quarter valued at $266,000. Sei Investments Co. bought a new stake in Sarepta Therapeutics in the third quarter valued at $1,013,000. New York State Common Retirement Fund boosted its holdings in Sarepta Therapeutics by 14.1% in the third quarter. New York State Common Retirement Fund now owns 63,300 shares of the biotechnology company’s stock valued at $2,871,000 after acquiring an additional 7,800 shares in the last quarter. Finally, Rhumbline Advisers boosted its holdings in Sarepta Therapeutics by 18.0% in the third quarter. Rhumbline Advisers now owns 72,543 shares of the biotechnology company’s stock valued at $3,291,000 after acquiring an additional 11,081 shares in the last quarter. Institutional investors and hedge funds own 84.98% of the company’s stock.

How to Become a New Pot Stock Millionaire

SRPT opened at $72.86 on Friday. The company has a quick ratio of 12.96, a current ratio of 13.91 and a debt-to-equity ratio of 0.54. The stock has a market capitalization of $4,715.48, a PE ratio of -44.43 and a beta of 1.29. Sarepta Therapeutics Inc has a 1 year low of $28.14 and a 1 year high of $84.37.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its quarterly earnings results on Thursday, March 1st. The biotechnology company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.32) by ($0.05). The company had revenue of $57.30 million during the quarter, compared to analysts’ expectations of $57.33 million. Sarepta Therapeutics had a negative return on equity of 30.59% and a negative net margin of 32.79%. Sarepta Therapeutics’s revenue for the quarter was up 961.1% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.71) EPS. sell-side analysts forecast that Sarepta Therapeutics Inc will post -1.18 earnings per share for the current fiscal year.

SRPT has been the topic of several recent analyst reports. Janney Montgomery Scott initiated coverage on shares of Sarepta Therapeutics in a report on Wednesday, January 3rd. They issued a “buy” rating and a $75.00 price target on the stock. HC Wainwright set a $75.00 target price on shares of Sarepta Therapeutics and gave the company a “buy” rating in a report on Wednesday, January 3rd. BidaskClub upgraded shares of Sarepta Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, January 13th. Oppenheimer restated a “buy” rating and set a $76.00 target price on shares of Sarepta Therapeutics in a report on Wednesday, December 27th. Finally, Nomura boosted their target price on shares of Sarepta Therapeutics to $96.00 and gave the company a “buy” rating in a report on Friday, March 2nd. Five investment analysts have rated the stock with a hold rating and nineteen have assigned a buy rating to the company. Sarepta Therapeutics presently has an average rating of “Buy” and an average price target of $76.40.

COPYRIGHT VIOLATION WARNING: This report was originally published by Ticker Report and is the property of of Ticker Report. If you are viewing this report on another site, it was copied illegally and reposted in violation of United States and international trademark & copyright law. The original version of this report can be viewed at https://www.tickerreport.com/banking-finance/3334204/sarepta-therapeutics-inc-srpt-position-trimmed-by-guggenheim-capital-llc.html.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).

Want to see what other hedge funds are holding SRPT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sarepta Therapeutics Inc (NASDAQ:SRPT).

Institutional Ownership by Quarter for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

BMO Capital Markets Cuts Africa Oil  Price Target to C$2.20
BMO Capital Markets Cuts Africa Oil Price Target to C$2.20
Baytex Energy  Given New C$4.50 Price Target at Raymond James
Baytex Energy Given New C$4.50 Price Target at Raymond James
Canadian National Railway  Given New C$107.00 Price Target at Royal Bank of Canada
Canadian National Railway Given New C$107.00 Price Target at Royal Bank of Canada
Enbridge  Price Target Lowered to C$53.00 at Scotiabank
Enbridge Price Target Lowered to C$53.00 at Scotiabank
COPYTRACK Price Tops $0.21 on Major Exchanges
COPYTRACK Price Tops $0.21 on Major Exchanges
Quantstamp  Price Up 30% This Week
Quantstamp Price Up 30% This Week


© 2006-2018 Ticker Report. Google+.